TLC 6740
Alternative Names: TLC-6740Latest Information Update: 26 Jun 2024
At a glance
- Originator Gilead Sciences
- Developer OrsoBio
- Class Antihypercalcaemics; Hepatoprotectants; Obesity therapies
- Mechanism of Action Mitochondrial oxidative phosphorylation uncouplers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Diabetes mellitus; Lipodystrophy; Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 24 Jun 2024 Efficacy data from a phase I trial in Obesity released by OrsoBio
- 24 Jun 2024 Pharmacodynamics data from a preclinical trial in Obesity released by OrsoBio
- 21 Jun 2024 Pharmacokinetics and adverse events data from a phase I trial in Obesity presented at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)